X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PIRAMAL ENTERPRISES - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PIRAMAL ENTERPRISES SANOFI INDIA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 30.9 38.2 81.0% View Chart
P/BV x 5.5 3.8 143.6% View Chart
Dividend Yield % 1.7 0.6 258.4%  

Financials

 SANOFI INDIA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
PIRAMAL ENTERPRISES
Mar-16
SANOFI INDIA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs4,5601,065 428.2%   
Low Rs4,400805 546.6%   
Sales per share (Unadj.) Rs1,028.5383.0 268.5%  
Earnings per share (Unadj.) Rs129.055.1 234.1%  
Cash flow per share (Unadj.) Rs186.074.1 251.1%  
Dividends per share (Unadj.) Rs68.0017.50 388.6%  
Dividend yield (eoy) %1.51.9 81.1%  
Book value per share (Unadj.) Rs753.6719.9 104.7%  
Shares outstanding (eoy) m23.03172.56 13.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.42.4 178.5%   
Avg P/E ratio x34.717.0 204.7%  
P/CF ratio (eoy) x24.112.6 190.8%  
Price / Book Value ratio x5.91.3 457.7%  
Dividend payout %52.731.8 166.0%   
Avg Mkt Cap Rs m103,174161,344 63.9%   
No. of employees `0003.63.8 95.8%   
Total wages/salary Rs m3,59216,898 21.3%   
Avg. sales/employee Rs Th6,537.717,472.6 37.4%   
Avg. wages/employee Rs Th991.44,466.9 22.2%   
Avg. net profit/employee Rs Th819.82,512.8 32.6%   
INCOME DATA
Net Sales Rs m23,68666,099 35.8%  
Other income Rs m7082,425 29.2%   
Total revenues Rs m24,39468,524 35.6%   
Gross profit Rs m5,28118,723 28.2%  
Depreciation Rs m1,3133,274 40.1%   
Interest Rs m159,388 0.2%   
Profit before tax Rs m4,6618,485 54.9%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,6911,032 163.9%   
Profit after tax Rs m2,9709,506 31.2%  
Gross profit margin %22.328.3 78.7%  
Effective tax rate %36.312.2 298.3%   
Net profit margin %12.514.4 87.2%  
BALANCE SHEET DATA
Current assets Rs m15,67347,488 33.0%   
Current liabilities Rs m6,678104,362 6.4%   
Net working cap to sales %38.0-86.0 -44.1%  
Current ratio x2.30.5 515.8%  
Inventory Days Days7641 187.1%  
Debtors Days Days2251 43.6%  
Net fixed assets Rs m8,09826,532 30.5%   
Share capital Rs m230345 66.7%   
"Free" reserves Rs m17,088114,024 15.0%   
Net worth Rs m17,356124,221 14.0%   
Long term debt Rs m075,812 0.0%   
Total assets Rs m25,400308,356 8.2%  
Interest coverage x311.71.9 16,373.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.2 435.0%   
Return on assets %11.86.1 191.8%  
Return on equity %17.17.7 223.6%  
Return on capital %26.910.0 270.5%  
Exports to sales %24.517.2 142.5%   
Imports to sales %28.06.6 423.8%   
Exports (fob) Rs m5,80111,362 51.1%   
Imports (cif) Rs m6,6274,364 151.9%   
Fx inflow Rs m7,14514,435 49.5%   
Fx outflow Rs m6,8465,183 132.1%   
Net fx Rs m2999,253 3.2%   
CASH FLOW
From Operations Rs m3,226-67,773 -4.8%  
From Investments Rs m-1,555-8,768 17.7%  
From Financial Activity Rs m-1,81876,199 -2.4%  
Net Cashflow Rs m-147-342 42.9%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 4.0 360.0%  
FIIs % 14.6 26.6 54.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   15,184 93,274 16.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 17, 2017 02:30 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - GLENMARK PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS